Virbac SA delivers robust first‑quarter 2026 performance

Virbac SA reported a 7.7 % increase in first‑quarter 2026 revenue at constant exchange rates and scope (CERS), reaching €384 million versus €356 million in the same period of 2025. The growth, driven by double‑digit expansion of the company’s priority Supercharge4 platforms, demonstrates that Virbac’s product portfolio is resonating across the global veterinary market.

Supercharge4: the engine behind the upside

Supercharge4—encompassing a range of high‑margin products such as Clostrisan, Effitix, and Iverhart—has become a cornerstone of Virbac’s strategy. The double‑digit gains reported for these platforms are a testament to the company’s ability to innovate and scale. By aligning R&D resources with commercial priorities, Virbac has maintained a clear focus on high‑performance solutions that address the most pressing needs of companion and food‑producing animal health.

Market context: a booming dewormer landscape

Industry outlooks underscore the relevance of Virbac’s core offerings. According to Market Research Intellect, the Farm Animal External Dewormer Market is projected to grow from €14.09 billion in 2025 to €34.92 billion by 2033 (CAGR 12.01 %). Likewise, the Pets External Dewormer Market is expected to rise from €9.27 billion in 2025 to €25.7 billion by 2033 (CAGR 13.59 %). These figures confirm that demand for deworming solutions—central to Virbac’s product mix—is accelerating worldwide, providing a fertile environment for the company’s continued expansion.

Geographic breadth fuels resilience

Virbac’s presence spans France, the rest of Europe, North America, Latin America, Asia‑Pacific, Africa, and the Middle East. This extensive footprint mitigates regional risks and allows the company to capitalize on divergent market dynamics. The 2026 Q1 results illustrate balanced growth across segments, suggesting that Virbac’s international strategy is effective and that its product pipeline is adaptable to varying regulatory and consumer landscapes.

Financial snapshot

  • Market Capitalisation: €3.01 billion
  • Price‑to‑Earnings Ratio: 36.15
  • Recent Closing Price (14 April 2026): €360.5
  • 52‑Week High/Low: €373.5 / €296

The valuation reflects investor expectations of sustained growth in a high‑margin segment that is becoming increasingly competitive. Yet, the company’s track record of delivering consistent revenue increases and expanding its high‑performing platforms suggests that the current valuation may still accommodate further upside.

Conclusion

Virbac’s first‑quarter 2026 performance is not merely a statistical win; it signals the efficacy of a disciplined focus on high‑value products within a rapidly expanding global dewormer market. The company’s ability to translate R&D excellence into commercial success, combined with a geographically diversified presence, positions Virbac well for continued leadership in animal health.